Exagen Inc., Allegheny Health Network Research Institute and AHN Autoimmunity Institute Announce Collaboration to Develop Novel Patented Biomarkers into Clinical Diagnostic Tests The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis, prognosis and monitoring of patients with autoimmune diseases May 04, 2021 16:05 ET | Source: Exagen Inc. Exagen Inc. Vista, California, UNITED STATES SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, AHN Autoimmunity Institute jointly announced today the execution of a research collaboration agreement and an exclusive license agreement. The collaboration will focus on the development of novel patented biomarkers for diagnosis, prognosis and monitoring of autoimmune diseases, including systemic lupus erythematosus (SLE).